Dimitri Grigoriadis the Chief Research Officer of Neurocrine Biosciences, Inc. (NBIX) Sold 23,000 Shares; Eventide Asset Management Increased Eaton Plc (ETN) Position By $339,700

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Logo

Eventide Asset Management Llc increased Eaton Corp Plc (ETN) stake by 33.86% reported in 2018Q1 SEC filing. Eventide Asset Management Llc acquired 4,300 shares as Eaton Corp Plc (ETN)’s stock declined 4.87%. The Eventide Asset Management Llc holds 17,000 shares with $1.36M value, up from 12,700 last quarter. Eaton Corp Plc now has $33.39 billion valuation. The stock decreased 2.03% or $1.58 during the last trading session, reaching $76.36. About 4.23 million shares traded or 45.62% up from the average. Eaton Corporation plc (NYSE:ETN) has risen 1.24% since June 22, 2017 and is uptrending. It has underperformed by 11.33% the S&P500. Some Historical ETN News: 03/04/2018 – ARENA MINERALS -FOLLOWING RESIGNATION OF EATON, DANIEL BRUNO HAS BEEN APPOINTED AS INTERIM CHAIRMAN OF BOARD OF DIRECTORS; 01/05/2018 – EATON CORP 1Q ADJ OPER EPS $1.10; 14/03/2018 Australian Gov: US Patent Issued to Eaton on March 13 for “Variable neutral impedance for multi-source system” (Ohio Inventor); 08/05/2018 – Eaton Named Among America’s Best Employers by Forbes; 08/05/2018 – Eaton Named Among America’s Best Employers by Forbes; 09/05/2018 – FORD – TO PROVIDE UPDATE ON RESPONSE TO SUPPLY ISSUE AS RESULT OF FIRE ON MAY 2 AT MERIDIAN MAGNESIUM PRODUCTS OF AMERICA FACTORY IN EATON RAPIDS; 29/03/2018 – Catalyst Pharmaceuticals Announces Submission of New Drug Application for Firdapse® for Treatment of Lambert-Eaton Myasthenic; 07/05/2018 – Eaton Demonstrates Transformational Possibilities of Connected Lighting for Today’s Smart Homes, Buildings and Communities at; 16/05/2018 – FORD MOTOR TO GIVE UPDATE ON MAY 2 FIRE AT EATON RAPIDS PLANT; 06/04/2018 – Eaton Corp Closes Below 200-Day Moving Average: Technicals

Eventide Asset Management Llc decreased Loxo Oncology Inc (NASDAQ:LOXO) stake by 56,000 shares to 229,000 valued at $26.42 million in 2018Q1. It also reduced Wave Life Sciences Ltd stake by 55,500 shares and now owns 378,000 shares. The Trade Desk Inc was reduced too.

Among 31 analysts covering Eaton Corporation (NYSE:ETN), 13 have Buy rating, 2 Sell and 16 Hold. Therefore 42% are positive. Eaton Corporation has $102.0 highest and $51 lowest target. $74.59’s average target is -2.32% below currents $76.36 stock price. Eaton Corporation had 94 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of Eaton Corporation plc (NYSE:ETN) has “Market Perform” rating given on Monday, May 2 by Bernstein. The rating was upgraded by Evercore to “Outperform” on Monday, May 7. The stock of Eaton Corporation plc (NYSE:ETN) earned “Sector Perform” rating by RBC Capital Markets on Thursday, February 4. The stock of Eaton Corporation plc (NYSE:ETN) earned “Hold” rating by Vertical Research on Wednesday, August 26. On Monday, January 9 the stock rating was upgraded by Bank of America to “Buy”. RBC Capital Markets maintained the stock with “Hold” rating in Monday, June 5 report. The firm has “Hold” rating given on Thursday, February 1 by RBC Capital Markets. JP Morgan downgraded the stock to “Neutral” rating in Friday, February 3 report. Avondale initiated Eaton Corporation plc (NYSE:ETN) rating on Thursday, October 15. Avondale has “Market Perform” rating and $60 target. Jefferies upgraded the stock to “Buy” rating in Monday, March 26 report.

More news for Eaton Corporation plc (NYSE:ETN) were recently published by: Seekingalpha.com, which released: “Honeywell, Dover among companies exiting Iran presence before sanctions” on June 05, 2018. Seekingalpha.com‘s article titled: “Wall Street Breakfast: ECB Steps Toward Exiting QE” and published on June 06, 2018 is yet another important article.

Investors sentiment decreased to 0.96 in 2018 Q1. Its down 0.19, from 1.15 in 2017Q4. It dropped, as 56 investors sold ETN shares while 302 reduced holdings. 76 funds opened positions while 266 raised stakes. 334.54 million shares or 0.90% more from 331.54 million shares in 2017Q4 were reported. Tocqueville Asset Management Limited Partnership invested in 0.01% or 8,116 shares. Natixis Advisors Lp holds 258,167 shares. Century Companies Inc has 2.24M shares. Annex Advisory Lc has invested 0.09% in Eaton Corporation plc (NYSE:ETN). Cwm invested 0.07% in Eaton Corporation plc (NYSE:ETN). Boyd Watterson Asset Mgmt Lc Oh holds 31,769 shares or 1.26% of its portfolio. Moreover, Cooke & Bieler Lp has 1.56% invested in Eaton Corporation plc (NYSE:ETN) for 1.04 million shares. Old Point Trust & Fin N A invested 0.66% of its portfolio in Eaton Corporation plc (NYSE:ETN). Loews holds 0% or 5,608 shares. Sandy Spring Bancorporation owns 1,573 shares for 0.01% of their portfolio. 21,821 were reported by Strategy Asset Managers Limited Liability Company. Zacks Investment has invested 1.09% of its portfolio in Eaton Corporation plc (NYSE:ETN). Blue Chip Ptnrs reported 0.95% in Eaton Corporation plc (NYSE:ETN). Livforsakringsbolaget Skandia Omsesidigt stated it has 6,739 shares. Lombard Odier Asset Mngmt (Switzerland) Sa reported 2,652 shares.

Looking at the deal Dimitri Grigoriadis made he is in the stock market focus today. The Chief Research Officer of Neurocrine Biosciences Inc and an insider, made a sale of 23,000 shares worth $2,415,000 U.S Dollars. The average price was $105.0 per share. He also unloaded 86,963 shares that are worth $8,650,738 USD in the last month. The chance that this transaction stays hidden is quite small due to the enormous amount of cash involved. At present, Dimitri Grigoriadis owns 82,942 shares which are equivalent to roughly 0.09% of Neurocrine Biosciences Inc’s market cap. More information about the transaction dated 21/06/2018, could be found available in an electronic report on the SEC website here.

More news for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) were recently published by: Benzinga.com, which released: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” on June 21, 2018. Benzinga.com‘s article titled: “Benzinga’s Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time” and published on June 01, 2018 is yet another important article.

Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on August, 2. They expect $-0.18 earnings per share, up 73.53% or $0.50 from last year’s $-0.68 per share. After $-0.47 actual earnings per share reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts -61.70% EPS growth.

Among 13 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 13 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Neurocrine Biosci has $139.0 highest and $58.0 lowest target. $101.38’s average target is -2.00% below currents $103.45 stock price. Neurocrine Biosci had 58 analyst reports since August 18, 2015 according to SRatingsIntel. Needham maintained the stock with “Buy” rating in Thursday, February 22 report. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Thursday, September 21 by Robert W. Baird. The rating was maintained by H.C. Wainwright on Tuesday, May 1 with “Buy”. BMO Capital Markets maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Friday, July 21 with “Buy” rating. BMO Capital Markets maintained it with “Buy” rating and $84.0 target in Tuesday, October 3 report. The rating was maintained by BMO Capital Markets with “Buy” on Friday, October 20. The company was maintained on Monday, September 25 by Cowen & Co. The firm has “Buy” rating given on Wednesday, November 1 by BMO Capital Markets. The company was maintained on Friday, August 4 by H.C. Wainwright. The rating was maintained by Piper Jaffray on Thursday, October 8 with “Overweight”.

Since January 2, 2018, it had 0 buys, and 28 selling transactions for $52.58 million activity. On Wednesday, January 24 the insider RASTETTER WILLIAM H sold $855,000. $175,090 worth of stock was sold by Lippoldt Darin on Monday, March 5. $1.20M worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was sold by BENEVICH ERIC on Friday, June 1. Another trade for 2,046 shares valued at $169,914 was made by Gano Kyle on Monday, February 5. 18,084 Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares with value of $1.40 million were sold by Lloyd-Smith Malcolm. OBrien Christopher Flint had sold 1,750 shares worth $138,499. Bozigian Haig P. had sold 75,873 shares worth $6.83 million on Monday, March 5.

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company has market cap of $9.30 billion. The company??s lead products include INGREZZA , a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women??s health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson??s disease. It currently has negative earnings. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Institutional Positions Chart